Literature DB >> 10923989

Dopamine and synaptic plasticity in the neostriatum.

G W Arbuthnott1, C A Ingham, J R Wickens.   

Abstract

After the unilateral destruction of the dopamine input to the neostriatum there are enduring changes in rat behaviour. These have been ascribed to the loss of dopamine and the animals are often referred to as 'hemiparkinsonian'. In the denervated neostriatum, we have shown that not only are the tyrosine hydroxylase positive boutons missing, but also the medium sized densely spiny output cells have fewer spines. Spines usually have asymmetric synapses on their heads. In a recent stereological study we were able to show that there is a loss of approximately 20% of asymmetric synapses in the lesioned neostriatum by 1 mo after the lesion. Current experiments are trying to establish the specificity of this loss. So far we have evidence suggesting that there is no obvious preferential loss of synapses from either D1 or D2 receptor immunostained dendrites in the neostriatum with damaged dopamine innervation. These experiments suggest that dopamine is somehow necessary for the maintenance of corticostriatal synapses in the neostriatum. In a different series of experiments slices of cortex and neostriatum were maintained in vitro in such a way as to preserve at least some of the corticostriatal connections. In this preparation we have been able to show that cortical stimulation results in robust excitatory postsynaptic potentials (EPSPs) recorded from inside striatal neurons. Using stimulation protocols derived from the experiments on hippocampal synaptic plasticity we have shown that the usual consequence of trains of high frequency stimulation of the cortex is the depression of the size of EPSPs in the striatal cell. In agreement with similar experiments by others, the effect seems to be influenced by NMDA receptors since the unblocking of these receptors with low Mg++ concentrations in the perfusate uncovers a potentiation of the EPSPs after trains of stimulation. Dopamine applied in the perfusion fluid round the slices has no effect but pulsatile application of dopamine, close to the striatal cell being recorded from, and in temporal association with the cortical trains, leads to a similar LTP like effect. The reduction of K+ channel conductance in the bath with TEA also has the effect of making cortical trains induce potentiation of corticostriatal transmission. TEA applied only to the cell being recorded from has no similar effect; the cortical stimulation again depresses the EPSP amplitude, so the site of action of TEA may well be presynaptic to the striatal cell. The morphological and physiological experiments may not necessarily be related but it is tempting to suggest that dopamine protects some corticostriatal synapses by potentiating them but that in the absence of dopamine others simply disconnect and are no longer detectable on electron microscopy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923989      PMCID: PMC1468099          DOI: 10.1046/j.1469-7580.2000.19640587.x

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  43 in total

1.  Double anterograde tracing of outputs from adjacent "barrel columns" of rat somatosensory cortex. Neostriatal projection patterns and terminal ultrastructure.

Authors:  A K Wright; L Norrie; C A Ingham; E A Hutton; G W Arbuthnott
Journal:  Neuroscience       Date:  1999-01       Impact factor: 3.590

2.  Function of catecholamine-containing neurones in mammalian central nervous system.

Authors:  T J Crow; G W Arbuthnott
Journal:  Nat New Biol       Date:  1972-08-23

3.  Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines.

Authors:  T F Freund; J F Powell; A D Smith
Journal:  Neuroscience       Date:  1984-12       Impact factor: 3.590

Review 4.  Dendritic spines for neuroprotection: a hypothesis.

Authors:  M Segal
Journal:  Trends Neurosci       Date:  1995-11       Impact factor: 13.837

5.  Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons.

Authors:  J Bargas; A Howe; J Eberwine; Y Cao; D J Surmeier
Journal:  J Neurosci       Date:  1994-11       Impact factor: 6.167

6.  Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated.

Authors:  C Cepeda; N A Buchwald; M S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum.

Authors:  J J Bouyer; D H Park; T H Joh; V M Pickel
Journal:  Brain Res       Date:  1984-06-08       Impact factor: 3.252

8.  Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.

Authors:  A I Levey; S M Hersch; D B Rye; R K Sunahara; H B Niznik; C A Kitt; D L Price; R Maggio; M R Brann; B J Ciliax
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

9.  Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum.

Authors:  K Campbell; A Björklund
Journal:  Eur J Neurosci       Date:  1994-08-01       Impact factor: 3.386

10.  Short- and long-term synaptic depression in rat neostriatum.

Authors:  D M Lovinger; E C Tyler; A Merritt
Journal:  J Neurophysiol       Date:  1993-11       Impact factor: 2.714

View more
  51 in total

1.  Simulating the effects of dopamine imbalance on cognition: from positive affect to Parkinson's disease.

Authors:  Sébastien Hélie; Erick J Paul; F Gregory Ashby
Journal:  Neural Netw       Date:  2012-02-20

2.  Observational versus feedback training in rule-based and information-integration category learning.

Authors:  F Gregory Ashby; W Todd Maddox; Corey J Bohil
Journal:  Mem Cognit       Date:  2002-07

3.  N-methyl-D-aspartate (NMDA) receptor composition modulates dendritic spine morphology in striatal medium spiny neurons.

Authors:  Csaba Vastagh; Fabrizio Gardoni; Vincenza Bagetta; Jennifer Stanic; Elisa Zianni; Carmen Giampà; Barbara Picconi; Paolo Calabresi; Monica Di Luca
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

4.  A neurocomputational account of cognitive deficits in Parkinson's disease.

Authors:  Sébastien Hélie; Erick J Paul; F Gregory Ashby
Journal:  Neuropsychologia       Date:  2012-06-08       Impact factor: 3.139

5.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

6.  Expanding the role of striatal cholinergic interneurons and the midbrain dopamine system in appetitive instrumental conditioning.

Authors:  Matthew J Crossley; Jon C Horvitz; Peter D Balsam; F Gregory Ashby
Journal:  J Neurophysiol       Date:  2015-10-14       Impact factor: 2.714

7.  AMPA/kainate, NMDA, and dopamine D1 receptor function in the nucleus accumbens core: a context-limited role in the encoding and consolidation of instrumental memory.

Authors:  Pepe J Hernandez; Matthew E Andrzejewski; Kenneth Sadeghian; Jules B Panksepp; Ann E Kelley
Journal:  Learn Mem       Date:  2005 May-Jun       Impact factor: 2.460

8.  Dual-task interference in perceptual category learning.

Authors:  Dagmar Zeithamova; W Todd Maddox
Journal:  Mem Cognit       Date:  2006-03

9.  Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.

Authors:  M D Neely; D E Schmidt; A Y Deutch
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

10.  Oxidative damage and neurodegeneration in manganese-induced neurotoxicity.

Authors:  Dejan Milatovic; Snjezana Zaja-Milatovic; Ramesh C Gupta; Yingchun Yu; Michael Aschner
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-14       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.